NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Phase 1

Completed

Conditions: Lymphoma, Extranodal NK-T-Cell
Enteropathy-Associated T-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell, Peripheral
Lymphoma, Large-Cell, Anaplastic

Interventions: Biological: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2017-02-10

Last Posted Date: 2023-01-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT03049449

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Phase 2

Active, not recruiting

Conditions: Locally Advanced Bladder Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Bladder Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Metastatic Transitional Cell Carcinoma
Stage IV Bladder Urothelial Carcinoma AJCC v7

Interventions: Drug: Sapanisertib

First Posted Date: 2017-02-08

Last Posted Date: 2025-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT03047213

Locations: 🇺🇸
Keck Medical Center of USC Pasadena, Pasadena, California, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 17 locations

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Decitabine
Drug: Navtemadlin
Drug: Venetoclax

First Posted Date: 2017-02-03

Last Posted Date: 2025-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT03041688

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 10 locations

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Phase 1

Terminated

Conditions: Rhabdomyosarcoma
Rhabdomyosarcoma, Embryonal
Rhabdomyosarcoma, Alveolar

Interventions: Drug: Dasatinib
Drug: Ganitumab

First Posted Date: 2017-02-03

Last Posted Date: 2022-04-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT03041701

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Phase 2

Completed

Conditions: KRAS NP_004976.2:p.G12R
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Selumetinib Sulfate

First Posted Date: 2017-02-02

Last Posted Date: 2021-02-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT03040986

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 6 locations

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Phase 2

Active, not recruiting

Conditions: High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Primary Effusion Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
ALK-Positive Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
EBV-Positive Mucocutaneous Ulcer

Interventions: Biological: Nivolumab
Drug: Varlilumab

First Posted Date: 2017-02-01

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT03038672

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 30 locations

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

Phase 2

Active, not recruiting

Conditions: Human Papillomavirus Infection
Human Papillomavirus-Related Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: HPV Self-Collection
Other: Questionnaire Administration
Biological: Recombinant Human Papillomavirus Nonavalent Vaccine

First Posted Date: 2017-01-31

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT03036930

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

and more 3 locations

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Phase 2

Completed

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Mucosal Melanoma
Melanoma of Unknown Primary
Unresectable Cutaneous Melanoma
Unresectable Melanoma

Interventions: Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2017-01-27

Last Posted Date: 2025-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 94

Registration Number: NCT03033576

Locations: 🇺🇸
Saint Joseph Hospital - Cancer Centers of Colorado, Denver, Colorado, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 634 locations

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Plasmacytoma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Dexamethasone Sodium Phosphate
Procedure: Echocardiography
Drug: Lenalidomide
Drug: Navtemadlin

First Posted Date: 2017-01-26

Last Posted Date: 2024-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT03031730

Locations: 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸
University of Texas at Austin, Austin, Texas, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

Completed

Conditions: Stomach Cancer
Hereditary Diffuse Gastric Cancer (HDGC)
Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS)
Familial Diffuse Gastric Cancer
Stomach Neoplasms

First Posted Date: 2017-01-25

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 733

Registration Number: NCT03030404

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy